BioMap Unveils 11 AI Life-Science Deals at Hong Kong Summit
BioMap announced 11 collaborations at the Hong Kong summit, spanning breast-cancer modeling, TCM research, crop breeding and a Singapore AI bio-computing center.
Topic
Drug Discovery
Topic
Drug Discovery
Anthropic’s IPO roadshow tests a less-than-decade AI cure claim
Anthropic CEO Dario Amodei says AI could make cancer, Alzheimer's, heart disease and mental illness relics of the past within a d…
Proximal Ventures Closes $27.5M for AI-Native Life Sciences
Proximal Ventures has closed its first fund at $27.5 million, exceeding a $25 million target, and will back pre-seed and seed AI-…
Norway's Vitroscope Raises $7 Million to Keep Living Tissue Under Flow
Trondheim biotech Vitroscope raised $7 million to roll out vitro.alive and validate vitro.scale, a 96-experiment perfusion system…
Anthropic Bets Big on Life Sciences Ahead of IPO
Anthropic's S-1 filing pitches drug discovery as its next business: a $400M biotech acquisition, 50,000 Claude seats at Lilly, an…
DropGenie Lands $5M Seed+ to Scale Gene-Editing in Scarce Patient Cells
DropGenie raised $5M in Seed+ funding from BDC Thrive, Skeleton Key, Merck's GHI Fund and others to scale a gene-editing platform…
Wall Street Used Claude to Design a Drug. Now It's a Trade.
Sell-side researchers used Anthropic's Claude to design a drug, and the experiment has already produced a new investment thesis f…
Aptadir Therapeutics Closes €40 Million Seed Round
Aptadir Therapeutics has closed a €40 million seed round, one of the larger early-stage biotech financings in Europe, the company…
The Real Payoff of the AI Boom May Be Better Medicines
U.S. healthcare spending hit $5.3 trillion in 2024. Enveda's executives argue drug discovery is where AI capacity converts most d…
Enveda Closes $311M Series E to Fuel Ambitions
Enveda has closed a $311 million Series E round, one of the year's larger biotech financings, to fund its stated ambition of beco…
Parabilis Aims for IPO After $800M Raise to Attack 'Undruggable' Targets
Parabilis has raised $800 million and is pursuing an IPO to fund drugs against "undruggable" targets, BioPharma Dive reports, tes…